{
  "nctId": "NCT04022226",
  "briefTitle": "EEG Characteristics in ECT",
  "officialTitle": "A Randomized Pilot Study Examining DCEEG Characteristics in Ketamine Versus Methohexital Induction in Depressed Patients Receiving Electroconvulsive Therapy",
  "protocolDocument": {
    "nctId": "NCT04022226",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-12-05",
    "uploadDate": "2024-08-05T13:32",
    "size": 381167,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04022226/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "EARLY_PHASE1"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 11,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-10-01",
    "completionDate": "2020-10-01",
    "primaryCompletionDate": "2020-10-01",
    "firstSubmitDate": "2019-07-10",
    "firstPostDate": "2019-07-17"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Structured Clinical Interview for DSM-5 will confirm diagnosis of MDD or BPD-depressed (with or without psychotic features\n* The clinical indications for ECT including treatment resistance or a need for a rapid and definitive response;\n* Hamilton Depression Rating Scale 24-item (HDRS-24) \\> 21; and\n* Age range between 18 and 65 years of age.\n\nExclusion Criteria:\n\n* Defined neurological or neurodegenerative disorder (e.g., history of head injury with loss of consciousness \\> 5 minutes, epilepsy, Alzheimer's disease);\n* Other psychiatric conditions (e.g., schizophrenia, schizoaffective disorder, bipolar disorder)\n* Current drug or alcohol use disorder, except for nicotine and marijuana\n* Adults unable to consent, pregnant women, prisoner\n* Non-English speakers\n* Patients that cannot tolerate Methohexital and Ketamine.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants Assessed for Clinical Efficacy of ECT",
        "description": "Quick Inventory of Depressive Symptomatology (QIDS) and Self Reporting version (QIDS-SR) - Range 0 - 48 with higher number indicating worsening depression.\n\nInadequate sample size due to COVID. Study was closed.",
        "timeFrame": "1 year"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 1
    },
    "studyDesign": {
      "phases": [
        "EARLY_PHASE1"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 39,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:18.738Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}